Administration mode |
Pharmacokinetic parameters(unit) |
Famitinib |
Famitinib |
Famitinib |
SHR116637 |
SHR116637 |
SHR116637 |
|
|
Mean ± SD
|
Geometric Mean (CV%)
|
Median
(minimum-maximum)
|
Mean ± SD
|
Geometric Mean (CV%)
|
Median
(minimum-maximum)
|
Famitinib |
Tmax* (h) |
5.65 ± 0.875 |
- |
6.00 (3.00, 7.00) |
5.8 ± 1.64 |
- |
5.00 (5.00,
12.00) |
|
Cmax (ng/mL) |
43.2 ± 7.8 |
42.5 (19.6) |
43.8 (25.7,
55.3) |
1.9 ± 0.5 |
1.8 (28.9) |
1.9 (1.2, 3.1) |
|
AUC0-t (h·ng/mL) |
1425.5 ± 296.3 |
1395.0
(22.1) |
1391.2 (778.0, 2052.3) |
115.8 ± 44.6 |
108.2 (39.4) |
108
(46.0, 201.4) |
|
AUC0-∞ (h·ng/mL) |
1450.8 ± 312.0 |
1417.9
(22.7) |
1407.1 (787.6, 2125.6) |
128.0 ± 52.2 |
118.9 (41.0) |
119.3
(50.8, 233.6) |
|
t1/2 (h) |
32.5 ± 5.6 |
32.1 (17.0) |
31.3
(24.6, 45.5) |
53.2 ± 9.4 |
52.4 (17.3) |
51.7 (40.0,
76.3) |
|
CL/F (L/h) |
18.1 ± 4.4 |
17.6 (22.7) |
17.8 (11.8, 31.7) |
- |
- |
- |
|
Vz/F (L) |
837.7 ± 221.2 |
815.3 (23.3) |
794.9 (529.6, 1606.4) |
- |
- |
- |
Famitinib + Omeprazole |
Tmax* (h) |
6.7 ± 1.03 |
|
6.50 (5.00, 8.00) |
6.9 ± 2.07 |
|
6.50 (5.0, 12.0) |
|
Cmax (ng/mL) |
42.7 ± 7.3 |
42.0 (18.2) |
42.4 (28.0,
57.6) |
1.6 ± 0.5 |
1.5 (33.5) |
1.5 (0.9, 2.8) |
|
AUC0-t (h·ng/mL) |
1355.0 ± 247.1 |
1333.2
(18.8) |
1312.7 (885.1, 1875.5) |
101.7 ± 34.6 |
96.3 (35.4) |
97.1
(53.9, 185.4) |
|
AUC0-∞ (h·ng/mL) |
1375.1 ± 257.0 |
1351.9
(19.3) |
1321.8 (895.1, 1915.0) |
111.7 ± 38.8 |
105.5 (36.1) |
106.9
(58.1, 203.3) |
|
t1/2 (h) |
32.0 ± 4.7 |
31.7 (14.0) |
30.7
(26.3, 44.5) |
52.8 ± 9.2 |
52.2 (16.3) |
51.6 (40.1,
81.5) |
|
CL/F (L/h) |
18.8 ± 3.7 |
18.5 (19.3) |
18.9 (13.1, 27.9) |
- |
- |
- |
|
Vz/F (L) |
859.7 ± 161.7 |
846.0 (18.4) |
825.6 (618.8, 1272.6) |
- |
- |
- |